摘要
背景:PDGFβ受体及其配体PDGF-BB在神经元损伤例如局部缺血后在体内被上调。当外源性应用时,PDGF-BB对兴奋性毒性和HIV蛋白具有神经保护作用。 目的:鉴于这种生长因子的神经保护能力,我们试图确定PDGF-BB是否会对抗淀粉样蛋白β(1-42)(与阿尔茨海默病(AD)有关的病理因素之一)具有神经保护作用。 方法和结果:在原代海马神经元和人源神经母细胞瘤细胞系SH-SY5Y中,淀粉样蛋白-β处理24小时以浓度依赖性方式降低存活细胞数目。用PDGF-BB预处理未能在初级神经元中提供针对淀粉样蛋白-β的任何神经保护作用,并且在SH-SY5Y细胞中仅有非常有限的保护作用。除了其神经保护作用外,PDGF促进几种系统中的细胞生长和分裂,并且将PDGFBB单独应用于血清饥饿的SH-SY5Y细胞导致细胞数目增加。淀粉样蛋白-β减弱了PDGF-BB的促有丝分裂效应,抑制了PDGF-BB诱导的PDGFβ受体磷酸化,并且减弱了PDGF-BB保护神经元抵抗NMDA诱导的兴奋性毒性的能力。尽管淀粉样蛋白-β抑制PDGFβ受体活化的能力,但免疫沉淀实验未能检测到淀粉样蛋白-β与PDGF-BB或PDGFβ受体之间的物理相互作用。然而,PDGFβ受体(专属细胞内信号传导途径)的G蛋白偶联受体反式激活仍然不受淀粉样β的存在影响。 结论:由于PDGF系统在神经元损伤时上调,淀粉样蛋白β抑制这种内源性神经保护系统的能力应在AD病理生理学的背景下进一步研究。
关键词: 淀粉样蛋白-β,PDGF-BB,PDGFβ受体,生长因子,神经保护,阿尔茨海默病。
Current Alzheimer Research
Title:Amyloid-β Inhibits PDGFβ Receptor Activation and Prevents PDGF-BBInduced Neuroprotection
Volume: 15 Issue: 7
关键词: 淀粉样蛋白-β,PDGF-BB,PDGFβ受体,生长因子,神经保护,阿尔茨海默病。
摘要: Background: PDGFβ receptors and their ligand, PDGF-BB, are upregulated in vivo after neuronal insults such as ischemia. When applied exogenously, PDGF-BB is neuroprotective against excitotoxicity and HIV proteins.
Objective: Given this growth factor's neuroprotective ability, we sought to determine if PDGF-BB would be neuroprotective against amyloid-β (1-42), one of the pathological agents associated with Alzheimer's disease (AD).
Methods and Results: In both primary hippocampal neurons and the human-derived neuroblastoma cell line, SH-SY5Y, amyloid-β treatment for 24 h decreased surviving cell number in a concentrationdependent manner. Pretreatment with PDGF-BB failed to provide any neuroprotection against amyloid-β in primary neurons and only very limited protective effects in SH-SY5Y cells. In addition to its neuroprotective action, PDGF promotes cell growth and division in several systems, and the application of PDGFBB alone to serum-starved SH-SY5Y cells resulted in an increase in cell number. Amyloid-β attenuated the mitogenic effects of PDGF-BB, inhibited PDGF-BB-induced PDGFβ receptor phosphorylation, and attenuated the ability of PDGF-BB to protect neurons against NMDA-induced excitotoxicity. Despite the ability of amyloid-β to inhibit PDGFβ receptor activation, immunoprecipitation experiments failed to detect a physical interaction between amyloid-β and PDGF-BB or the PDGFβ receptor. However, G protein-coupled receptor transactivation of the PDGFβ receptor (an exclusively intracellular signaling pathway) remained unaffected by the presence of amyloid-β.
Conclusions: As the PDGF system is upregulated upon neuronal damage, the ability of amyloid-β to inhibit this endogenous neuroprotective system should be further investigated in the context of AD pathophysiology.
Export Options
About this article
Cite this article as:
Amyloid-β Inhibits PDGFβ Receptor Activation and Prevents PDGF-BBInduced Neuroprotection, Current Alzheimer Research 2018; 15 (7) . https://dx.doi.org/10.2174/1567205015666180110110321
DOI https://dx.doi.org/10.2174/1567205015666180110110321 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Congenital Malformations Attributed to Prenatal Exposure to Cyclophosphamide
Anti-Cancer Agents in Medicinal Chemistry Extracellular Targeting of Synthetic Therapeutic Nucleic Acid Formulations
Current Gene Therapy Role of Advanced Glycation End Products in Diabetic Neuropathy
Current Pharmaceutical Design Recent Development of Peptide Drugs and Advance on Theory and Methodology of Peptide Inhibitor Design
Medicinal Chemistry Anti-Inflammatory and Pro-Resolving Effects of N-3 PUFA in Cancers: Structures and Mechanisms
Current Topics in Medicinal Chemistry Targeting Cell Death in Tumors by Activating Caspases
Current Cancer Drug Targets Effects of Early Maternal Separation on Biobehavioral and Neuropathological Markers of Alzheimer's Disease in Adult Male Rats
Current Alzheimer Research Apoptosis Induction by Erucylphosphohomocholine via the 18 kDa Mitochondrial Translocator Protein: Implications for Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Fluorine-18 Labeled Amino Acids for Oncologic Imaging with Positron Emission Tomography
Current Topics in Medicinal Chemistry Tubulins as Therapeutic Targets in Cancer: from Bench to Bedside
Current Pharmaceutical Design Neuronal Acetylcholine Nicotinic Receptors as New Targets for Lung Cancer Treatment
Current Pharmaceutical Design Pharmacological Overview and Future Perspectives of Cholinergic Therapy in Alzheimers Disease
Current Drug Therapy The Role of Clusterin in Carcinogenesis and its Potential Utility as Therapeutic Target
Current Medicinal Chemistry Pharmacoproteomics Applications for Drug Target Discovery in CNS Disorders
Current Pharmacogenomics and Personalized Medicine Expression, Distribution and Regulation of Phosphodiesterase 5
Current Pharmaceutical Design Recent Advances in Improving Sub-Unit Vaccine Efficacy Using Cytokines as more Specific Immune Inducing Adjuvants
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Melatonin and Renal Protection: Novel Perspectives from Animal Experiments and Human Studies (Review)
Current Pharmaceutical Design Indoleamine 2,3-Dioxygenase in Immune Suppression and Cancer
Current Cancer Drug Targets Contemporary Anticholinesterase Pharmaceuticals of Natural Origin and Their Synthetic Analogues for the Treatment of Alzheimers Disease
Recent Patents on CNS Drug Discovery (Discontinued) SOCS6 Functions as a Tumor Suppressor by Inducing Apoptosis and Inhibiting Angiogenesis in Human Prostate Cancer
Current Cancer Drug Targets